Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyJonathan P. Piccini, Veronika Eder, Valeria Caso et al.|The Lancet|2022Cited by 310
Skeletal Muscle Function, Structure, and Metabolism in Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection FractionTarek Bekfani, P. Christian Schulze, U. Smolenski et al.|Circulation Heart Failure|2020Cited by 83
A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failureMichael Lichtenauer, Rudin Pistulli, Peter Jirak et al.|European Journal of Internal Medicine|2017Cited by 65
Clinical implications of fetuin-APeter Jirak, Hermann Salmhofer, Lars Stechemesser et al.|Advances in clinical chemistry|2019Cited by 62
A second space age spanning omics, platforms and medicine across orbitsChristopher E. Mason, Cem Meydan, James Green et al.|Nature|2024Cited by 50